{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:41:41Z","timestamp":1768506101760,"version":"3.49.0"},"posted":{"date-parts":[[2023,2,27]]},"group-title":"Pharmacology and Toxicology","reference-count":42,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Most aggressive lymphomas are treated with combination chemotherapy, commonly as multiple cycles of concurrent drug administration. Concurrent administration is in theory optimal when combination therapies have synergistic (more than additive) drug interactions. We investigated pharmacodynamic interactions in the standard 4-drug \u2018CHOP\u2019 regimen in Peripheral T-Cell Lymphoma (PTCL) cell lines, and found that CHOP consistently exhibits antagonism and not synergy. We tested whether staggered treatment schedules could improve tumor cell kill by avoiding antagonism, using month-long\n                  <jats:italic>in vitro<\/jats:italic>\n                  models of concurrent or staggered treatments. Surprisingly, we observed that tumor cell kill is maximized by concurrent drug administration despite antagonistic drug-drug interactions. We propose that an ultrasensitive dose response, as described in radiology by the linear-quadratic (LQ) model, can reconcile these seemingly contradictory experimental observations. The LQ model describes the relationship between cell survival and dose, and in radiology has identified scenarios favoring hypofractionated radiation \u2013 the administration of fewer large doses rather than multiple smaller doses. Specifically, hypofractionated treatment can be favored when cells require an accumulation of DNA damage, rather than a \u2018single hit\u2019, in order to die. By adapting the LQ model to combination chemotherapy and accounting for tumor heterogeneity, we find that tumor cell kill is maximized by concurrent administration of multiple drugs, even when chemotherapies have antagonistic interactions. Thus, our study identifies a new mechanism by which combination chemotherapy can be clinically beneficial that is not reliant on positive drug-drug interactions.\n                <\/jats:p>","DOI":"10.1101\/2023.02.27.530263","type":"posted-content","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T23:10:13Z","timestamp":1677539413000},"source":"Crossref","is-referenced-by-count":1,"title":["Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-895X","authenticated-orcid":false,"given":"Sarah C.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-3539","authenticated-orcid":false,"given":"Amy E.","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-7028","authenticated-orcid":false,"given":"Adam C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023030803051414000_2023.02.27.530263v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.04.025"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-020-00561-w","article-title":"Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma","volume":"15","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"2023030803051414000_2023.02.27.530263v1.3","unstructured":"CHOP Patient Information [Internet]. Cancer Care Ontario. [cited 2022 Jul 26]. Available from: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/53586"},{"issue":"2 Suppl 2","key":"2023030803051414000_2023.02.27.530263v1.4","first-page":"15","article-title":"Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer","volume":"10","year":"1983","journal-title":"Semin Oncol"},{"key":"2023030803051414000_2023.02.27.530263v1.5","doi-asserted-by":"crossref","first-page":"577215","DOI":"10.3389\/fcell.2020.577215","article-title":"Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro","volume":"8","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/btm2.10082","article-title":"Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation","volume":"3","year":"2018","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.1986.4.1.23","article-title":"Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma","volume":"4","year":"1986","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.8","doi-asserted-by":"crossref","first-page":"12830","DOI":"10.1038\/s41598-019-49073-5","article-title":"Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"2023030803051414000_2023.02.27.530263v1.9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50036"},{"key":"2023030803051414000_2023.02.27.530263v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2008.04.004"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.11","doi-asserted-by":"crossref","first-page":"01TR01","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: usage, interpretation and challenges","volume":"64","year":"2018","journal-title":"Phys Med Biol"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.12","first-page":"5848","volume-title":"Nat Commun","volume":"11","year":"2020"},{"issue":"8","key":"2023030803051414000_2023.02.27.530263v1.13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1381612805666230110215458","article-title":"The chemistry of the metabolites of cyclophosphamide","volume":"5","year":"1999","journal-title":"Curr Pharm Des"},{"key":"2023030803051414000_2023.02.27.530263v1.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5546.205"},{"key":"2023030803051414000_2023.02.27.530263v1.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111840"},{"issue":"12","key":"2023030803051414000_2023.02.27.530263v1.16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","year":"2019","journal-title":"Drug Discov Today"},{"issue":"2","key":"2023030803051414000_2023.02.27.530263v1.17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying Drug Combination Synergy along Potency and Efficacy Axes","volume":"8","year":"2019","journal-title":"Cell Syst"},{"issue":"6","key":"2023030803051414000_2023.02.27.530263v1.18","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"2023030803051414000_2023.02.27.530263v1.19","doi-asserted-by":"crossref","unstructured":"Huang R yue , Pei L , Liu Q , Chen S , Dou H , Shu G , Yuan Z xiang , Lin J , Peng G , Zhang W , Fu H. Isobologram Analysis: A Comprehensive Review of Methodology and Current Research. Front Pharmacol [Internet]. 2019 Oct 29 [cited 2021 Mar 22];10. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6830115\/ PMCID: PMC6830115","DOI":"10.3389\/fphar.2019.01222"},{"key":"2023030803051414000_2023.02.27.530263v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"issue":"5","key":"2023030803051414000_2023.02.27.530263v1.21","first-page":"1417","article-title":"A Mechanistic, Predictive Model of Dose-Response Curves for Cell Cycle Phase-specific and -nonspecific Drugs1","volume":"60","year":"2000","journal-title":"Cancer Res"},{"key":"2023030803051414000_2023.02.27.530263v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2009.09.015"},{"issue":"2","key":"2023030803051414000_2023.02.27.530263v1.23","first-page":"93","article-title":"What is synergy?","volume":"41","year":"1989","journal-title":"Pharmacol Rev"},{"key":"2023030803051414000_2023.02.27.530263v1.24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0009"},{"key":"2023030803051414000_2023.02.27.530263v1.25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.16.1205"},{"issue":"11","key":"2023030803051414000_2023.02.27.530263v1.26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","year":"1984","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"2023030803051414000_2023.02.27.530263v1.27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.13565","article-title":"Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia\/lymphoma","volume":"106","year":"2021","journal-title":"Eur J Haematol"},{"key":"2023030803051414000_2023.02.27.530263v1.28","first-page":"43","article-title":"Dose intensity versus total dose of chemotherapy: an experimental basis","year":"1990","journal-title":"Important Adv Oncol"},{"issue":"3","key":"2023030803051414000_2023.02.27.530263v1.29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/cts.12951","article-title":"Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations","volume":"14","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"2","key":"2023030803051414000_2023.02.27.530263v1.30","first-page":"197","article-title":"Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience","volume":"30","year":"2009","journal-title":"Prilozi"},{"issue":"1","key":"2023030803051414000_2023.02.27.530263v1.31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12957-021-02150-4","article-title":"Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer","volume":"19","year":"2021","journal-title":"World J Surg Oncol"},{"key":"2023030803051414000_2023.02.27.530263v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25087"},{"key":"2023030803051414000_2023.02.27.530263v1.33","doi-asserted-by":"crossref","unstructured":"West J , Desai B , Strobl M , Pierik L , Velde RV , Armagost C , Miles R , Robertson-Tessi M , Marusyk A , Anderson ARA. Antifragile therapy [Internet]. bioRxiv; 2021 [cited 2023 Feb 14]. p. 2020.10.08.331678. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2020.10.08.331678v2","DOI":"10.1101\/2020.10.08.331678"},{"key":"2023030803051414000_2023.02.27.530263v1.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"issue":"3","key":"2023030803051414000_2023.02.27.530263v1.35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2023030803051414000_2023.02.27.530263v1.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"2023030803051414000_2023.02.27.530263v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.03.009"},{"issue":"2","key":"2023030803051414000_2023.02.27.530263v1.38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0165-4608(92)90215-T","article-title":"Characterization of a novel T-cell lymphoma cell line established from a patient with systemic lupus erythematosus-associated lymphoma","volume":"59","year":"1992","journal-title":"Cancer Genet Cytogenet"},{"key":"2023030803051414000_2023.02.27.530263v1.39","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000177224.19294.92"},{"key":"2023030803051414000_2023.02.27.530263v1.40","doi-asserted-by":"crossref","unstructured":"Yang F , Jiang M , Lu M , Hu P , Wang H , Jiang J. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. Front Pharmacol [Internet]. 2018 [cited 2020 Aug 20];9. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2018.00991\/full","DOI":"10.3389\/fphar.2018.00991"},{"issue":"2","key":"2023030803051414000_2023.02.27.530263v1.41","first-page":"215","volume":"8","year":"1982","journal-title":"The pharmacokinetics of vincristine in man: Cancer Chemother Pharmacol"},{"key":"2023030803051414000_2023.02.27.530263v1.42","unstructured":"Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2021 Feb 18]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.02.27.530263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:19:17Z","timestamp":1768450757000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.02.27.530263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1101\/2023.02.27.530263","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1158\/1535-7163.MCT-23-0642","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,2,27]]},"subtype":"preprint"}}